Bioptimus, an AI foundation model company, announced that it has reached a significant funding milestone of $76 million. This total funding includes a $41 million cash injection, led by Cathay Innovation with participation from prominent investors, including Sofinnova Partners, Bpifrance through its Large Venture Fund, Andera Partners, Hitachi Ventures, Boom Capital Ventures, Pomifer Capital, Sunrise, and angel entrepreneurs Emmanuel Cassimatis and Thomas Wolf.
This funding will accelerate Bioptimus’s goal of building the world’s first universal AI foundation model for biology, aimed at revolutionizing research and innovation across the medical, biotech, cosmetic industries, and beyond.
The company has been building momentum this year as it assembled a world-class team, securing access to unique data sources, and successfully releasing its first model, H-Optimus-0, the world’s largest foundation model for pathology. And H-Optimus-0 already outperformed all other pathology models in independent benchmarks, including assessments conducted by Harvard Medical School’s HEST program and the University of Leeds. These studies highlighted the model’s ability to accurately predict gene expression from morphology and subtype ovarian cancer.
Bioptimus is transforming how we approach biological research by addressing a longstanding issue: the siloed nature of biological understanding. Research has historically focused on isolated biological components, such as DNA, proteins, cells, or tissues. Even existing AI foundation models operate within these silos, limiting their potential impact. Bioptimus’s revolutionary approach integrates data across multiple scales (molecules, cells, tissues, organisms) and modalities (imaging, genetics, etc), enabling a holistic view of biology as it exists in reality.
This funding will enable Bioptimus to enhance its multi-modal AI platform, integrating even more diverse data sources and therapeutic areas, forge strategic partnerships with pharmaceutical and biotech companies and expand critical datasets to further refine and validate its models.
By combining AI with a truly integrated view of biology, Bioptimus will enable researchers and multiple industries to solve some of the most complex challenges in medicine, biotechnology, and beyond.
KEY QUOTES:
“What we are building is not just a technological breakthrough; it’s a transformative tool for understanding biology in its full complexity. By learning how biology works directly from raw data across scales, from molecules to whole organisms, our model will empower researchers in the pharmaceutical industry to simulate complex biology, predict disease outcomes and response to treatment, and design therapies with unprecedented precision. Beyond pharmaceuticals, this model will unlock limitless possibilities across many other industries, driving biological discoveries in ways we are only beginning to imagine. Essentially, it’s like the GPT of biology—but instead of generating text, we’re simulating biology.”
– Jean-Philippe Vert, co-founder and CEO of Bioptimus
“Bioptimus is at the forefront of transforming biological research, leveraging cutting-edge AI to break down silos and unlock the full complexity of biology. By integrating data across multiple scales and modalities, Bioptimus is paving the way for groundbreaking innovations across industries, from pharmaceuticals to biotechnology and beyond. We are delighted to see that since our initial investment a year ago, Bioptimus has succeeded in structuring a world-class team, while achieving key milestones in its development, notably with the launch of its AI foundation model for pathology in July, the largest in the world.”
– Jacky Abitbol, Partner at Cathay Innovation
